SCM
VIVO

Siphron Capital Management’s Meridian Bioscience Inc VIVO Stock Holding History

Siphron Capital Management’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-96
Closed -$2K – 76
2014
Q2 		$2K Hold
96
– – 0.01% 71
2014
Q1 		$2K Hold
96
– – ﹤0.01% 69
2013
Q4 		$3K Hold
96
– – ﹤0.01% 44
2013
Q3 		$2K Hold
96
– – ﹤0.01% 74
2013
Q2 		$2K Buy
+96
New +$2.07K ﹤0.01% 73

Other funds holding VIVO

BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

Siphron Capital Management's VIVO Position: Q3 2014 in Review

Siphron Capital Management sold out of Meridian Bioscience Inc (VIVO) in Q3 2014, closing a stake of 96 shares — an estimated $2K sold.

Siphron Capital Management first reported a position in VIVO in Q2 2013 and held it in 5 quarters. The position peaked at $3K in Q4 2013. 161 funds tracked by Wall St. Rank hold VIVO as of Q3 2014.

  • Siphron Capital Management reported no remaining Meridian Bioscience Inc position as of Q3 2014 after selling out during the quarter.
  • Siphron Capital Management sold 96 Meridian Bioscience Inc shares in Q3 2014, an estimated $2K.
  • Siphron Capital Management first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 5 quarters.
  • Siphron Capital Management's Meridian Bioscience Inc position peaked at $3K in Q4 2013.
  • 161 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2014.

Based on Siphron Capital Management's 13F filing for Q3 2014, filed 13 Nov 2014.